201 related articles for article (PubMed ID: 27990784)
1. New findings on inhibitor development: from registries to clinical studies.
Peyvandi F; Ettingshausen CE; Goudemand J; Jiménez-Yuste V; Santagostino E; Makris M
Haemophilia; 2017 Jan; 23 Suppl 1():4-13. PubMed ID: 27990784
[TBL] [Abstract][Full Text] [Related]
2. ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.
Oldenburg J; Austin SK; Kessler CM
Haemophilia; 2014 Sep; 20 Suppl 6():17-26. PubMed ID: 24975701
[TBL] [Abstract][Full Text] [Related]
3. New predictive approaches for ITI treatment.
Minno GD; Santagostino E; Pratt K; Königs C
Haemophilia; 2014 Sep; 20 Suppl 6():27-43. PubMed ID: 24975702
[TBL] [Abstract][Full Text] [Related]
4. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
5. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
[TBL] [Abstract][Full Text] [Related]
6. More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance.
Santagostino E
Haemophilia; 2013 Jan; 19 Suppl 1():8-11. PubMed ID: 23278994
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia.
Batorova A; Jankovicova D; Morongova A; Bubanska E; Prigancova T; Horakova J; Machyniakova M; Cervenka J; Chandoga J; Böhmer D; Mistrik M
Semin Thromb Hemost; 2016 Jul; 42(5):550-62. PubMed ID: 27235830
[TBL] [Abstract][Full Text] [Related]
8. Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study.
Rivard GE; Rothschild C; Toll T; Achilles K
Haemophilia; 2013 May; 19(3):449-55. PubMed ID: 23510123
[TBL] [Abstract][Full Text] [Related]
9. Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis.
Kenet G; Oladapo A; Epstein JD; Thompson C; Novack A; Nugent DJ
Haemophilia; 2017 Sep; 23(5):e394-e402. PubMed ID: 28641362
[TBL] [Abstract][Full Text] [Related]
10. Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens.
Lin PC; Liao YM; Tsai SP; Chang TT
Pediatr Blood Cancer; 2011 Dec; 57(6):1029-33. PubMed ID: 21793191
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic bypassing agent use before and during immune tolerance induction in patients with haemophilia A and inhibitors to FVIII.
Carpenter SL; Khair K; Gringeri A; Valentino LA
Haemophilia; 2018 Jul; 24(4):570-577. PubMed ID: 29901839
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors in patients with haemophilia A.
Kreuz W; Ettingshausen CE
Thromb Res; 2014 Nov; 134 Suppl 1():S22-6. PubMed ID: 24745722
[TBL] [Abstract][Full Text] [Related]
13. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
Mannucci PM; Shi Q; Bonanad S; Klamroth R
Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors in haemophilia A: current management and open issues.
Haya S; Moret A; Cid AR; Cortina V; Casaña P; Cabrera N; Aznar JA
Haemophilia; 2007 Dec; 13 Suppl 5():52-60. PubMed ID: 18078398
[TBL] [Abstract][Full Text] [Related]
15. Forum on: the role of recombinant factor VIII in children with severe haemophilia A.
Franchini M; Coppola A; Molinari AC; Santoro C; Schinco P; Speciale V; Tagliaferri A
Haemophilia; 2009 Mar; 15(2):578-86. PubMed ID: 19187188
[TBL] [Abstract][Full Text] [Related]
16. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.
Gringeri A; Musso R; Mazzucconi MG; Piseddu G; Schiavoni M; Pignoloni P; Mannucci PM;
Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550
[TBL] [Abstract][Full Text] [Related]
17. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment.
Earnshaw SR; Graham CN; McDade CL; Spears JB; Kessler CM
Haemophilia; 2015 May; 21(3):310-319. PubMed ID: 25688580
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy.
Abbonizio F; Giampaolo A; Coppola A; ; Arcieri R; Hassan HJ
Haemophilia; 2014 Jul; 20(4):e243-50. PubMed ID: 24834967
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI.
Thom K; Male C; Falger J; Pabinger I
Hamostaseologie; 2009 May; 29(2):149-50. PubMed ID: 19404512
[TBL] [Abstract][Full Text] [Related]
20. [Prophylaxis in patients with haemophilia complicated by inhibitors].
Paweł Ł
Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
